Evidence map›Paper›PMID 39391934›Full record

ArticleBrain : a journal of neurology2025

Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum.

Marketta Kachemov, Vineet Vaibhav, Charlene Smith, Niveda Sundararaman, Marie Heath, Devon F Pendlebury, Andrea Matlock, Alice Lau, Eva Morozko, Ryan G Lim and 4 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. A Landscape Analysis of Human SUMOylation.Molecular & cellular proteomics : MCP · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marketta KachemovNeurobiology and Behavior, University of California Irvine, Irvine, CA 92697, USA.
Vineet VaibhavAdvanced Clinical Biosystems Research Institute, The Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Charlene SmithDepartment of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA 92868, USA.
Niveda SundararamanAdvanced Clinical Biosystems Research Institute, The Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Marie HeathNeurobiology and Behavior, University of California Irvine, Irvine, CA 92697, USA.
Devon F PendleburyNeurobiology and Behavior, University of California Irvine, Irvine, CA 92697, USA.
Andrea MatlockAdvanced Clinical Biosystems Research Institute, The Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Alice LauSue and Bill Gross Stem Cell Center, University of California Irvine, Irvine, CA 92697, USA.
Eva MorozkoNeurobiology and Behavior, University of California Irvine, Irvine, CA 92697, USA.
Ryan G LimInstitute of Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA 92697, USA.
Jack ReidlingInstitute of Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, CA 92697, USA.
Joan S SteffanDepartment of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA 92868, USA.
Jennifer E Van EykAdvanced Clinical Biosystems Research Institute, The Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Leslie M ThompsonNeurobiology and Behavior, University of California Irvine, Irvine, CA 92697, USA.ORCID 0000-0003-4573-9514

Funding

Neuron and Glial Cellular Signatures from Normal and Diseased iPS Cells-SupplementU54NS091046 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI FINKBEINER, STEVEN M, FRAENKEL, ERNEST · 2014 to 2020
$11.7M
Molecular Mechanisms of Pathogenesis in Huntington’s diseaseR35NS116872 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Leslie Michels Thompson · 2020 to 2026
$8.5M
Neuroregulatory Mechanisms of PIAS1 and Implications for Huntington's DiseaseR01NS090390 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI DAVIDSON, BEVERLY L., THOMPSON, LESLIE MICHELS · 2015 to 2018
$1.8M
Cedars-Sinai Proteomics and Metabolomics CoreCIRMErika Glazer Endowed Chair in Women's Heart HealthHD CAREHereditary Disease FoundationNIHNIH HHS R35 NS116872NINDS NIH HHS R01 NS090390NINDS NIH HHS R35 NS116872NINDS NIH HHS U54 NS091046NSF
6 · The paper itself

Abstract

Huntington's disease is a neurodegenerative disorder caused by an expanded CAG repeat mutation in the Huntingtin (HTT) gene. The mutation impacts neuronal protein homeostasis and cortical/striatal circuitry. SUMOylation is a post-translational modification with broad cellular effects including via modification of synaptic proteins. Here, we used an optimized SUMO protein-enrichment and mass spectrometry method to identify the protein SUMOylation/SUMO interaction proteome in the context of Huntington's disease using R6/2 transgenic and non-transgenic mice. Significant changes in the enrichment of SUMOylated and SUMO-interacting proteins were observed, including those involved in presynaptic function, cytomatrix at the active zone, cytoskeleton organization and glutamatergic signalling. Mitochondrial and RNA-binding proteins also showed altered enrichment. Modified SUMO-associated pathways in Huntington's disease tissue include clathrin-mediated endocytosis signalling, synaptogenesis signalling, synaptic long-term potentiation and SNARE signalling. To evaluate how modulation of SUMOylation might influence functional measures of neuronal activity in Huntington's disease cells in vitro, we used primary neuronal cultures from R6/2 and non-transgenic mice. A receptor internalization assay for the metabotropic glutamate receptor 7 (mGLUR7), a SUMO-enriched protein in the mass spectrometry, showed decreased internalization in R6/2 neurons compared to non-transgenic neurons. SiRNA-mediated knockdown of the E3 SUMO ligase protein inhibitor of activated STAT1 (Pias1), which can SUMO modify mGLUR7, reduced this Huntington's disease phenotype. In addition, microelectrode array analysis of primary neuronal cultures indicated early hyperactivity in Huntington's disease cells, while later time points demonstrated deficits in several measurements of neuronal activity within cortical neurons. Huntington's disease phenotypes were rescued at selected time points following knockdown of Pias1. Collectively, our results provide a mouse brain SUMOome resource and show that significant alterations occur within the post-translational landscape of SUMO-protein interactions of synaptic proteins in Huntington's disease mice, suggesting that targeting of synaptic SUMO networks may provide a proteostatic systems-based therapeutic approach for Huntington's disease and other neurological disorders.

Indexed as

Corpus StriatumHuntington DiseaseSumoylationAnimalsCells, CulturedDisease Models, AnimalHuntingtin ProteinMaleMiceMice, TransgenicNeuronsReceptors, Metabotropic GlutamateHuntingtin ProteinReceptors, Metabotropic GlutamateE3 SUMO ligaseHuntington’s diseasemGLUR7PIAS1proteomicsSUMOsynaptic

Identifiers

PMID39391934
PMCPMC11969464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.